CA2685214A1 - Forme posologique orale a liberation regulee amelioree - Google Patents

Forme posologique orale a liberation regulee amelioree Download PDF

Info

Publication number: CA2685214A1
Authority: CA; Canada
Prior art keywords: composition; bupropion; cellulose; pharmaceutically acceptable; acceptable salt
Prior art date: 2001-02-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002685214A

Other languages

English (en)

Other versions

CA2685214C (fr

Inventor

Boyong Li

Chih-Ming Chen

Xiu Xiu Cheng

Avinash Nangia

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Andrx Pharmaceuticals LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-08

Filing date

2002-02-08

Publication date

2002-08-15

2002-02-08 Application filed by Individual filed Critical Individual

2002-02-08 Priority to CA2796884A priority Critical patent/CA2796884A1/fr

2002-08-15 Publication of CA2685214A1 publication Critical patent/CA2685214A1/fr

2013-01-22 Application granted granted Critical

2013-01-22 Publication of CA2685214C publication Critical patent/CA2685214C/fr

2022-02-08 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000013270 controlled release Methods 0.000 title claims description 23
239000006186 oral dosage form Substances 0.000 title description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims abstract description 110
229960001058 bupropion Drugs 0.000 claims abstract description 98
239000012730 sustained-release form Substances 0.000 claims abstract description 29
238000013268 sustained release Methods 0.000 claims abstract description 27
150000003839 salts Chemical class 0.000 claims abstract description 19
239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
239000008188 pellet Substances 0.000 claims description 95
239000000203 mixture Substances 0.000 claims description 89
239000011248 coating agent Substances 0.000 claims description 34
238000000576 coating method Methods 0.000 claims description 33
239000002775 capsule Substances 0.000 claims description 23
229920002678 cellulose Polymers 0.000 claims description 19
239000001913 cellulose Substances 0.000 claims description 18
239000003826 tablet Substances 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 14
235000010980 cellulose Nutrition 0.000 claims description 14
239000011230 binding agent Substances 0.000 claims description 13
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 11
239000001856 Ethyl cellulose Substances 0.000 claims description 10
229920001249 ethyl cellulose Polymers 0.000 claims description 10
235000019325 ethyl cellulose Nutrition 0.000 claims description 10
229920001688 coating polymer Polymers 0.000 claims description 9
229920003176 water-insoluble polymer Polymers 0.000 claims description 9
230000001419 dependent effect Effects 0.000 claims description 8
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 8
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 8
229940117841 methacrylic acid copolymer Drugs 0.000 claims description 8
230000036470 plasma concentration Effects 0.000 claims description 7
229920000642 polymer Polymers 0.000 claims description 7
239000008187 granular material Substances 0.000 claims description 6
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims description 4
229920001747 Cellulose diacetate Polymers 0.000 claims description 4
229920002284 Cellulose triacetate Polymers 0.000 claims description 4
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
229920002301 cellulose acetate Polymers 0.000 claims description 4
229920006217 cellulose acetate butyrate Polymers 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 3
229920001800 Shellac Polymers 0.000 claims description 2
239000007894 caplet Substances 0.000 claims description 2
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
238000001727 in vivo Methods 0.000 claims description 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical group OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
239000004208 shellac Substances 0.000 claims description 2
229940113147 shellac Drugs 0.000 claims description 2
235000013874 shellac Nutrition 0.000 claims description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 description 29
229940079593 drug Drugs 0.000 description 26
239000003814 drug Substances 0.000 description 26
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
239000000047 product Substances 0.000 description 14
239000002552 dosage form Substances 0.000 description 13
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 12
238000000034 method Methods 0.000 description 12
239000000454 talc Substances 0.000 description 10
229910052623 talc Inorganic materials 0.000 description 10
235000012222 talc Nutrition 0.000 description 10
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
239000000935 antidepressant agent Substances 0.000 description 8
238000004090 dissolution Methods 0.000 description 8
239000004014 plasticizer Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
229940018503 zyban Drugs 0.000 description 8
IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 7
229960004367 bupropion hydrochloride Drugs 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
-1 hydroxypropyl Chemical group 0.000 description 7
239000000463 material Substances 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
239000003844 drug implant Substances 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
230000003111 delayed effect Effects 0.000 description 5
238000009505 enteric coating Methods 0.000 description 5
239000002702 enteric coating Substances 0.000 description 5
HEYVINCGKDONRU-UHFFFAOYSA-N Bupropion hydrochloride Chemical compound Cl.CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 HEYVINCGKDONRU-UHFFFAOYSA-N 0.000 description 4
229920003141 Eudragit® S 100 Polymers 0.000 description 4
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000036765 blood level Effects 0.000 description 4
238000007922 dissolution test Methods 0.000 description 4
238000013265 extended release Methods 0.000 description 4
239000007888 film coating Substances 0.000 description 4
238000009501 film coating Methods 0.000 description 4
239000012530 fluid Substances 0.000 description 4
229940075507 glyceryl monostearate Drugs 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
229920002126 Acrylic acid copolymer Polymers 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002051 biphasic effect Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000083869 Polyommatus dorylas Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008199 coating composition Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000000151 deposition Methods 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000012466 permeate Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000009877 rendering Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007939 sustained release tablet Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
YXZRCLVVNRLPTP-UHFFFAOYSA-J turquoise blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Cu+2].NC1=NC(Cl)=NC(NC=2C=C(NS(=O)(=O)C3=CC=4C(=C5NC=4NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)NC=4NC(=C6C=C(C=CC6=4)S([O-])(=O)=O)NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)N5)C=C3)C(=CC=2)S([O-])(=O)=O)=N1 YXZRCLVVNRLPTP-UHFFFAOYSA-J 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
SPTDJSJAWJDTNY-SREVYHEPSA-N CCC(C)OC(C)/C=C(/C)\N Chemical compound CCC(C)OC(C)/C=C(/C)\N SPTDJSJAWJDTNY-SREVYHEPSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012186 Delayed delivery Diseases 0.000 description 1
MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
229920003149 Eudragit® E 100 Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
208000025307 bipolar depression Diseases 0.000 description 1
BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
229920003118 cationic copolymer Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000005056 compaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
229960002380 dibutyl phthalate Drugs 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
229960002097 dibutylsuccinate Drugs 0.000 description 1
VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000002386 leaching Methods 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000010082 neurochemical mechanism Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000010499 rapseed oil Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
229940124535 smoking cessation aid Drugs 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)

CA2685214A 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree Expired - Fee Related CA2685214C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2796884A CA2796884A1 (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US26745601P	2001-02-08	2001-02-08
US26745701P	2001-02-08	2001-02-08
US60/267,457		2001-02-08
US60/267,456		2001-02-08
CA2433915A CA2433915C (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2433915A Division CA2433915C (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2796884A Division CA2796884A1 (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Publications (2)

Publication Number	Publication Date
CA2685214A1 true CA2685214A1 (fr)	2002-08-15
CA2685214C CA2685214C (fr)	2013-01-22

Family

ID=26952450

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CA2433915A Expired - Fee Related CA2433915C (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree
CA2796884A Abandoned CA2796884A1 (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree
CA2685214A Expired - Fee Related CA2685214C (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CA2433915A Expired - Fee Related CA2433915C (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree
CA2796884A Abandoned CA2796884A1 (fr)	2001-02-08	2002-02-08	Forme posologique orale a liberation regulee amelioree

Country Status (3)

Country	Link
EP (1)	EP1357898A4 (fr)
CA (3)	CA2433915C (fr)
WO (1)	WO2002062299A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8545880B2 (en)	1999-02-26	2013-10-01	Andrx Pharmaceuticals, Llc	Controlled release oral dosage form
ME00391B (me)	2003-08-08	2011-10-10	Biovail Laboratories Int Srl	Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
CN101146521A (zh) *	2005-03-14	2008-03-19	太阳医药高级研究有限公司	提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
JP2010510320A (ja) *	2006-11-21	2010-04-02	マクニール−ピーピーシー・インコーポレーテツド	改変型放出鎮痛性懸濁液
US9833510B2 (en)	2007-06-12	2017-12-05	Johnson & Johnson Consumer Inc.	Modified release solid or semi-solid dosage forms
EP2437733A4 (fr) *	2009-06-02	2014-01-08	Dow Global Technologies Llc	Forme posologique à libération prolongée
CN110200947A (zh) *	2019-06-27	2019-09-06	深圳市泛谷药业股份有限公司	一种安非他酮肠溶缓释微丸胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0653935B1 (fr) *	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Composition pharmaceutique sous forme de granules
GB9217295D0 (en) *	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
US6270805B1 (en) *	1998-11-06	2001-08-07	Andrx Pharmaceuticals, Inc.	Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6210716B1 (en) *	1999-02-26	2001-04-03	Andrx Pharmaceuticals, Inc.	Controlled release bupropion formulation

2002
- 2002-02-08 CA CA2433915A patent/CA2433915C/fr not_active Expired - Fee Related
- 2002-02-08 EP EP02723104A patent/EP1357898A4/fr not_active Withdrawn
- 2002-02-08 CA CA2796884A patent/CA2796884A1/fr not_active Abandoned
- 2002-02-08 CA CA2685214A patent/CA2685214C/fr not_active Expired - Fee Related
- 2002-02-08 WO PCT/US2002/003523 patent/WO2002062299A2/fr not_active Ceased

Also Published As

Publication number	Publication date
CA2433915A1 (fr)	2002-08-15
EP1357898A4 (fr)	2005-07-13
EP1357898A2 (fr)	2003-11-05
WO2002062299A3 (fr)	2003-04-24
CA2796884A1 (fr)	2002-08-15
CA2685214C (fr)	2013-01-22
CA2433915C (fr)	2010-04-20
WO2002062299A2 (fr)	2002-08-15

Legal Events

Date	Code	Title	Description
2009-11-18	EEER	Examination request
2021-10-12	MKLA	Lapsed	Effective date: 20210831
2022-10-07	MKLA	Lapsed	Effective date: 20200210

Publication	Publication Date	Title
US8545880B2 (en)	2013-10-01	Controlled release oral dosage form
US6589553B2 (en)	2003-07-08	Controlled release oral dosage form
JP2637981B2 (ja)	1997-08-06	吸収制御薬剤組成物
CA2686094A1 (fr)	2010-08-24	Methode de fabrication d'un element semiconducteur
AU2002330211B2 (en)	2007-02-01	Timed, sustained release multi-particulate dosage forms of propranolol
EP1879556B1 (fr)	2013-07-10	Systemes de liberation chronocontrolee par impulsions
AU757915B2 (en)	2003-03-13	Controlled release bupropion formulation
HUE029680T2 (en)	2017-02-28	Dispensing systems containing weakly basic active ingredients and organic acids
US10213389B2 (en)	2019-02-26	Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
KR20080007252A (ko)	2008-01-17	양성 전립선 과다형성증용 치료 조합물
US20030035840A1 (en)	2003-02-20	Controlled release oral dosage form
HU227490B1 (en)	2011-07-28	Sustained release pharmaceutical preparation containing carvedilol
CA2433915C (fr)	2010-04-20	Forme posologique orale a liberation regulee amelioree
WO2007117110A2 (fr)	2007-10-18	Granules à libération prolongée contenant du chlorhydrate de tamsulosine et leurs procédés de préparation
EP1629834A1 (fr)	2006-03-01	Composition pharmaceutique de tolterodine avec liberation soutenue
US20090297602A1 (en)	2009-12-03	Modified Release Loxoprofen Compositions
JP2005510449A (ja)	2005-04-21	改良型制御放出経口剤形
AU2002253907A1 (en)	2002-08-19	Improved controlled release oral dosage form
AU2013273835B2 (en)	2016-07-07	Timed, pulsatile release systems
HK1108116B (en)	2014-03-21	Timed, pulsatile release systems